Information Provided By: 
Fly News Breaks for August 7, 2019
GWPH
Aug 7, 2019 | 08:27 EDT
Morgan Stanley analyst David Lebowitz raised his 2019 Epidiolex sales estimate to $291M from $165M after GW Pharmaceuticals report sales that "easily exceeded consensus" in the drug's second full quarter on the U.S. market. The analyst, who noted that significant adoption from adult patients continues and management continues to anticipate dose to increase as physicians become more comfortable administering, raised his price target on GW Pharmaceuticals shares to $238 and keeps an Overweight rating on the stock.
News For GWPH From the Last 2 Days
There are no results for your query GWPH
